155 related articles for article (PubMed ID: 12160239)
1. Characterization of soluble CD40 ligand released from human activated platelets.
Jin Y; Nonoyama S; Morio T; Imai K; Ochs HD; Mizutani S
J Med Dent Sci; 2001 Mar; 48(1):23-7. PubMed ID: 12160239
[TBL] [Abstract][Full Text] [Related]
2. Matrix metalloproteinase 9 is involved in Crohn's disease-associated platelet hyperactivation through the release of soluble CD40 ligand.
Menchén L; Marín-Jiménez I; Arias-Salgado EG; Fontela T; Hernández-Sampelayo P; Rodríguez MC; Butta NV
Gut; 2009 Jul; 58(7):920-8. PubMed ID: 19039088
[TBL] [Abstract][Full Text] [Related]
3. Analysis of serum soluble CD40 ligand (sCD40L) in the patients undergoing allogeneic stem cell transplantation: platelet is a major source of serum sCD40L.
Nagasawa M; Zhu Y; Isoda T; Tomizawa D; Itoh S; Kajiwara M; Morio T; Nonoyama S; Shimizu N; Mizutani S
Eur J Haematol; 2005 Jan; 74(1):54-60. PubMed ID: 15613107
[TBL] [Abstract][Full Text] [Related]
4. [From gene to disease; CD40 ligand deficiency as the cause of X-linked hyper-IgM-syndrome].
Groeneweg M; Lankester AC; Bredius RG
Ned Tijdschr Geneeskd; 2003 May; 147(21):1009-11. PubMed ID: 12811971
[TBL] [Abstract][Full Text] [Related]
5. Soluble CD40 ligand in pulmonary arterial hypertension: possible pathogenic role of the interaction between platelets and endothelial cells.
Damås JK; Otterdal K; Yndestad A; Aass H; Solum NO; Frøland SS; Simonsen S; Aukrust P; Andreassen AK
Circulation; 2004 Aug; 110(8):999-1005. PubMed ID: 15302794
[TBL] [Abstract][Full Text] [Related]
6. Short-term treatment with atorvastatin reduces platelet CD40 ligand and thrombin generation in hypercholesterolemic patients.
Sanguigni V; Pignatelli P; Lenti L; Ferro D; Bellia A; Carnevale R; Tesauro M; Sorge R; Lauro R; Violi F
Circulation; 2005 Feb; 111(4):412-9. PubMed ID: 15687128
[TBL] [Abstract][Full Text] [Related]
7. Neutrophil CD40 enhances platelet-mediated inflammation.
Vanichakarn P; Blair P; Wu C; Freedman JE; Chakrabarti S
Thromb Res; 2008; 122(3):346-58. PubMed ID: 18289643
[TBL] [Abstract][Full Text] [Related]
8. Coexpression of normal and mutated CD40 ligand with deletion of a putative RNA lariat branchpoint sequence in X-linked hyper-IgM syndrome.
Zhu X; Chung I; O'Gorman MR; Scholl PR
Clin Immunol; 2001 Jun; 99(3):334-9. PubMed ID: 11358428
[TBL] [Abstract][Full Text] [Related]
9. Release of soluble CD40 ligand after platelet activation: studies on the solubilization phase.
Otterdal K; Pedersen TM; Solum NO
Thromb Res; 2004; 114(3):167-77. PubMed ID: 15342213
[TBL] [Abstract][Full Text] [Related]
10. Increased concentrations of soluble CD40 ligand, RANTES and GRO-alpha in preeclampsia--possible role of platelet activation.
Mellembakken JR; Solum NO; Ueland T; Videm V; Aukrust P
Thromb Haemost; 2001 Nov; 86(5):1272-6. PubMed ID: 11816717
[TBL] [Abstract][Full Text] [Related]
11. Elevated release of sCD40L from platelets of diabetic patients by thrombin, glucose and advanced glycation end products.
Varo N; Libby P; Nuzzo R; Italiano J; Doria A; Schönbeck U
Diab Vasc Dis Res; 2005 May; 2(2):81-7. PubMed ID: 16308911
[TBL] [Abstract][Full Text] [Related]
12. Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients.
Danese S; Katz JA; Saibeni S; Papa A; Gasbarrini A; Vecchi M; Fiocchi C
Gut; 2003 Oct; 52(10):1435-41. PubMed ID: 12970136
[TBL] [Abstract][Full Text] [Related]
13. Human platelets can activate peripheral blood B cells and increase production of immunoglobulins.
Cognasse F; Hamzeh-Cognasse H; Lafarge S; Chavarin P; Cogné M; Richard Y; Garraud O
Exp Hematol; 2007 Sep; 35(9):1376-87. PubMed ID: 17656005
[TBL] [Abstract][Full Text] [Related]
14. Somatic mutations in human Ig variable genes correlate with a partially functional CD40-ligand in the X-linked hyper-IgM syndrome.
Razanajaona D; van Kooten C; Lebecque S; Bridon JM; Ho S; Smith S; Callard R; Banchereau J; Brière F
J Immunol; 1996 Aug; 157(4):1492-8. PubMed ID: 8759730
[TBL] [Abstract][Full Text] [Related]
15. CD40 ligand mutations in x-linked immunodeficiency with hyper-IgM.
DiSanto JP; Bonnefoy JY; Gauchat JF; Fischer A; de Saint Basile G
Nature; 1993 Feb; 361(6412):541-3. PubMed ID: 8094231
[TBL] [Abstract][Full Text] [Related]
16. The CD40/CD40 ligand system: linking inflammation with atherothrombosis.
Antoniades C; Bakogiannis C; Tousoulis D; Antonopoulos AS; Stefanadis C
J Am Coll Cardiol; 2009 Aug; 54(8):669-77. PubMed ID: 19679244
[TBL] [Abstract][Full Text] [Related]
17. Molecular characterization of patients with X-linked Hyper-IgM syndrome: description of two novel CD40L mutations.
Rangel-Santos A; Wakim VL; Jacob CM; Pastorino AC; Cunha JM; Collanieri AC; Niemela JE; Grumach AS; Duarte AJ; Moraes-Vasconcelos D; Oliveira JB
Scand J Immunol; 2009 Feb; 69(2):169-73. PubMed ID: 19170966
[TBL] [Abstract][Full Text] [Related]
18. Platelet soluble CD40L and matrix metalloproteinase 9 activity are proinflammatory mediators in Behçet disease patients.
Fernández Bello I; Álvarez MT; López-Longo FJ; Arias-Salgado EG; Martín M; Jiménez-Yuste V; Rodríguez de la Rúa A; Butta NV
Thromb Haemost; 2012 Jan; 107(1):88-98. PubMed ID: 22116092
[TBL] [Abstract][Full Text] [Related]
19. Preliminary evidence for a matrix metalloproteinase-2 (MMP-2)-dependent shedding of soluble CD40 ligand (sCD40L) from activated platelets.
Reinboldt S; Wenzel F; Rauch BH; Hohlfeld T; Grandoch M; Fischer JW; Weber AA
Platelets; 2009 Sep; 20(6):441-4. PubMed ID: 19811225
[TBL] [Abstract][Full Text] [Related]
20. Intravenous immunoglobulins induce CD32-mediated platelet aggregation in vitro.
Pollreisz A; Assinger A; Hacker S; Hoetzenecker K; Schmid W; Lang G; Wolfsberger M; Steinlechner B; Bielek E; Lalla E; Klepetko W; Volf I; Ankersmit HJ
Br J Dermatol; 2008 Sep; 159(3):578-84. PubMed ID: 18565176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
